// App-Quantinova.ai

273.0 : Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.

Researchers

Presenter

  • Michael Lee

Principal Investigators

  • Laura Williamson

  • James Thomas Topham

  • Sean Addison

  • Hui-Li Wong

  • Rob Denroche

  • Gun Ho Jang

  • Joanna Karasinska

  • John Paul McGhie

  • Sharlene Gill

  • Howard John Lim

  • Stephen Yip

  • Jennifer J. Knox

  • Steven Gallinger

  • Janessa J. Laskin

  • Marco A. Marra

  • Steven J. M. Jones

  • David F Sschaeffer

  • Daniel John Renouf

  • POG PDAC

Medical Centers

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Genome Sciences Centre, Vancouver, BC, Canada

  • Canada's Michael Smith Genome Sciences Centre, Vancouver, BC, Canada

  • Pancreas Centre BC, Vancouver, BC, Canada

  • Vancouver General Hospital, Internal Medicine Department, Vancouver, BC, Canada

  • Royal Melbourne Hospital, Victoria, Australia

  • Ontario Institute for Cancer Research, Toronto, ON, Canada

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • BC Cancer Agency, Vancouver, BC, Canada

  • BC Cancer Agency, Vancouver, BC, Canada

  • Vancouver Coastal Health Research Institute, Vancouver, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada

  • Department of Pathology and Laboratory Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada

Locations

  • Canada

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreas ductal adenocarcinoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved